Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.43 |
| ▸ | MPO | P05164 | 5/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23656514 | 0.82 | HTT (0.54) | SMN1; SMN2MAPTMPOHTT | |
| SCHEMBL19007004 | 0.82 | SOS2 (0.46) | HTR2ASMN1; SMN2MAPTNPSR1SOS2 | |
| SCHEMBL4803628 | 0.79 | HTR2A (0.71) | HTR2ASMN1; SMN2MAPTNPSR1SOS2 | |
| SCHEMBL10252339 | 0.78 | MPO (0.49) | HTR2ASMN1; SMN2MAPTNPSR1MPO | |
| SCHEMBL5477550 | 0.78 | MPO (0.49) | HTR2ASMN1; SMN2MAPTNPSR1MPO | |
| SCHEMBL4803022 | 0.78 | HTT (0.55) | HTR2ASMN1; SMN2MAPTNPSR1MPO | |
| SCHEMBL9157617 | 0.77 | DAO (0.40) | NPSR1GABRA1GABRG2GABRB3 | |
| SCHEMBL4797230 | 0.76 | GABRA1 (0.40) | HTR2ASLC6A4GABRA1HTR2C | |
| SCHEMBL11539380 | 0.76 | HTR2A (0.54) | HTR2ASMN1; SMN2MAPTNPSR1MPO | |
| SCHEMBL18999655 | 0.76 | PARP14 (0.50) | HTR2ASOS2GABRA1GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7446122-B2 | Substituted indole derivatives | CEPHALON, INC. (US) | 2008-11-04 | — | — | US | disclosed |
| US-7314886-B2 | Tetrahydropyrano-indole derivatives | CEPHALON, INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-20070244180-A1 | Substituted indole derivatives | SALMEDIX, INC. | 2007-10-18 | — | — | US | disclosed |
| US-20060166947-A1 | Multiple myeloma treatments | DANA-FARBER CANCER INSTITUTE, INC. | 2006-07-27 | — | — | US | disclosed |
| US-20060160876-A1 | (6-Bromo-1,8-diethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-acetic acid ethyl ester; antineoplastic, anti-inflammatory, analgesic | SALMEDIX, INC. | 2006-07-20 | — | — | US | disclosed |
| EP-1680428-A2 | SUBSTITUTED INDOLE DERIVATIVES | CEPHALON, INC. (US) | 2006-07-19 | — | — | EP | disclosed |
| EP-1673373-A2 | INDOLE DERIVATIVES | Salmedix, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005033112-A2 | SUBSTITUTED INDOLE DERIVATIVES | CEPHALON, INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| WO-2005033113-A2 | INDOLE DERIVATIVES | CEPHALON, INC (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244180-A1 | Substituted indole derivatives | IDO1, IDO2, HTR3A | HTR2A 12/4885SMN1; SMN2 4397/4885MAPT 639/4885 |
| US-20060160876-A1 | (6-Bromo-1,8-diethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-acetic acid ethyl ester; antineoplastic, anti-inflammatory, analgesic | IL6, OPRK1, PTGES3 | HTR2A 360/4885SMN1; SMN2 3333/4885MAPT 2112/4885 |
| US-20060166947-A1 | Multiple myeloma treatments | BCL6, MCL1, BCL6B | HTR2A 2275/4885SMN1; SMN2 2921/4885MAPT 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.